JAK3 covalent inhibitor-2
Product Specifications
Target
Apoptosis, JAK
Related Pathways
JAK/STAT signaling, Chromatin/Epigenetic, Tyrosine Kinase/Adaptors, Apoptosis, Stem Cells, Angiogenesis
Bioactivity
JAK3covalent inhibitor-2 (compound J1b) is a selective JAK3 inhibitor with oral efficacy, boasting an IC50 value of 7.2 nM. It is characterized by low toxicity, anti-inflammatory properties, and excellent bioavailability.
Shipping Conditions
Ice Packs
Storage Temperature
-20°C
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC471003-500 1x 500 µL
Mucin 5AC (MUC5AC) (58M1), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC400977-100 1x 100 µL
TGF-beta (1D11.16.8), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040630-500 1x 500 µL
Mucin 1 / EMA / Episialin / CD227 (VU-2G7), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC400257-100 1x 100 µL
Cytokeratin, HMW (AE-3), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC400003-500 1x 500 µL
CD45RO (UCHL-1), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details